704 Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models

• Kate Sasser,
• Kristel Kemper,
• Ellis Gielen,
• Mischa Houtkamp,
• Peter Boross,
• Stefanie De Poot,
• Patrick Engelberts,
• Bart de Goeij,
• David Satijn

Affiliations

Kate Sasser

Genmab, Princeton, NJ, USA

Kristel Kemper

Genmab, Utrecht, Netherlands

Ellis Gielen

Genmab, Utrecht, Netherlands

Mischa Houtkamp

Genmab, Utrecht, Netherlands

Peter Boross

Genmab, Utrecht, Netherlands

Stefanie De Poot

Genmab, Utrecht, Netherlands

Patrick Engelberts

Genmab, Utrecht, Netherlands

Bart de Goeij

Genmab, Utrecht, Netherlands

David Satijn

Genmab, Utrecht, Netherlands